Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNO155 in combination with spartalizumab or ribociclib in advanced solid tumors
NCT04000529Phase 1Terminated
- Sponsor
- Novartis
- Start
- Jul 2019
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 1, open-label trial of batoprotafib in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC) and 2 more (2 arms), sponsored by Novartis. Primary endpoints: Dose-Limiting Toxicity Incidence at 1 year, Adverse Event Incidence at 3 years and 2 more. Started Jul 2019; status: terminated.
02
Drugs
batoprotafib
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)gastrointestinal stromal tumor (GIST)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04000529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04000529.